Agomelatine reduces circulating triacylglycerides and hepatic steatosis in fructose-treated rats - 03/09/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 12 |
| Iconographies | 9 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Agomelatine (AGO) is an antidepressant drug with agonistic activity at melatonin receptor 1 (MT1) and MT2 and with neutral antagonistic activity at serotonin receptor 5-HT2C. Although experimental studies show that melatonin reduces hypertriglyceridemia and hepatic steatosis induced by excessive fructose intake, no studies have tested if AGO exerts similar actions. To address this issue we have treated male Wistar rats with fructose (15% in the drinking water) and/or AGO (40 mg/kg/day) for two weeks. AGO reduced body weight gain, feeding efficiency and hepatic lipid levels without affecting caloric intake in fructose-treated rats. AGO has also decreased very low-density lipoprotein (VLDL) production and circulating TAG levels after an oral load with olive oil. Accordingly, treatment with AGO reduced the hepatic expression of fatty acid synthase (Fasn), a limiting step for hepatic de novo lipogenesis (DNLG). The expression of apolipoprotein B (Apob) and microsomal triglyceride transfer protein (Mttp) in the ileum, two crucial proteins for intestinal lipoprotein production, were also downregulated by treatment with AGO. Altogether, the present data show that AGO mimics the metabolic benefits of melatonin when used in fructose-treated rats. This study also suggests that it is relevant to evaluate the potential of AGO to treat metabolic disorders in future clinical trials.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Agomelatine reduces circulating triacylglycerides in fructose-treated rats. |
• | Agomelatine reduces hepatic lipids in fructose-treated rats. |
• | Agomelatine reduces ileal Mttp and Apob expression in fructose-treated rats. |
• | Agomelatine reduces triglycerides after olive oil gavage in fructose-treated rats. |
Keywords : Agomelatine, Fructose, Lipid metabolism, Hepatic steatosis, Melatonin
Plan
Vol 141
Article 111807- septembre 2021 Retour au numéro
Article précédent
- Peroxiredomin-4 ameliorates lipotoxicity-induced oxidative stress and apoptosis in diabetic cardiomyopathy
- Bin Zhang, Xiaoya Li, Guoxin Liu, Chenyang Zhang, Xuelian Zhang, Qiang Shen, Guibo Sun, Xiaobo Sun
- Effect of Nigella sativa, atorvastatin, or L-Carnitine on high fat diet-induced obesity in adult male Albino rats
- Mohammed Esmail, Shehata Anwar, Mohammed Kandeil, Ali Mahmoud El-Zanaty, Mohammed Abdel-Gabbar
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?